(AOF) – Amplitude Surgical announces consolidated turnover up 11.2% at constant rates in the second quarter, to 28.55 million euros. The specialist in surgical technologies intended for orthopedics for the lower limbs specifies that during the first half of the year, turnover stood at 49.1 million euros, an increase of 8.5% and 9.4%. at constant rates. “In France, which represents approximately 71% of the Group’s activity, Amplitude Surgical continues to benefit from favorable commercial dynamics,” specifies the medtech.
“During the first half of the 2023-24 financial year, Amplitude Surgical continued its growth from the previous financial year and posted an increase of +9.4% at constant rates compared to the first half of 2022-23” underlines the director General Olivier Jallabert.
“Activity progressed both in France with growth of 8.1% and internationally with growth of 12.8% at constant rates.”
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.